Palivizumab is a monoclonal antibody directed against respiratory syncytial virus (RSV) and an effective prophylactic against severe infection in high risk infants. A new trial in preterm infants reports that the drug also helps prevent …
Get access to this article and to all of thebmj.com for 14 days.
Sign up today for a 14 day free trial.
Access to the full version of this article requires a subscription payment.